Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Teclistamab with daratumumab for previously treated relapsed or refractory multiple myeloma	Daratumumab (Darzalex; JNJ-54767414) , Teclistamab	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2022	View \| Download
Teclistamab for previously treated relapsed or refractory multiple myeloma	Teclistamab	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2022	View \| Download
Tecarfarin for preventing venous thromboembolism	Tecarfarin (ATI-5923)	Thromboembolism	Cardiovascular System , Haematology	2020	View \| Download
Tazemetostat for treating relapsed or refractory follicular lymphoma after two therapies	Tazemetostat (E7438;EPZ-6438;Tazverik)	Follicular lymphoma	Haematological Cancer and Lymphomas	2023	View \| Download
Taselisib in Combination with Fulvestrant for Advanced ER Positive, HER2-negative Breast Cancer – Second Line After Aromatase Inhibitor Therapy	Fulvestrant (Faslodex) , Taselisib (GDC-0032; RG-7604)	Breast cancer	Breast Cancer	2017	View \| Download
TAS-102 with bevacizumab for treating refractory metastatic colorectal cancer after 2 previous therapies	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Lonsurf; TAS-102 (fixed dose combination: Trifluridine; Tipiracil hydrochloride)	Colorectal cancer	Gastrointestinal Cancer , Oncology	2023	View \| Download
Tarlatamab for relapsed/refractory small-cell lung cancer	Tarlatamab	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2023	View \| Download
Targeted-release budesonide for treating primary IgA nephropathy	Budesonide targeted-release (Nefecon; PL-56)	Primary IgA nephropathy	Immunology , Nephrology	2024	View \| Download
Tanezumab for moderate to severe chronic pain associated with osteoarthritis and chronic low back pain	Tanezumab (PF-04383119; RN624)	Back pain , Osteoarthritic pain	Musculoskeletal System , Pain Relief , Rheumatology	2019	View \| Download
Tanezumab for cancer pain due to bone metastasis	Tanezumab (PF-04383119; RN624)	Cancer pain	Bone and Cartilage Cancer , Oncology	2020	View \| Download